NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC , a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the exclusive rights to a new and promising tumor treatment using an RNAi based therapeutic technology for the potential use against a broad range of cancers.
This technology, which specifically targets a novel cancer biomarker, was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.
Frank Massino, CEO and Chairman of Senetek, commented, “We are extremely pleased that our relationship with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences has resulted in another important addition to our technology portfolio. We look forward to the opportunities that lie ahead with this novel advancement in RNAi therapy.”
About Senetek PLC
Senetek PLC is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company’s extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company’s website at http://www.senetekplc.com.
This news release contains statements that may be considered ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
CONTACT: William O’Kelly of Senetek PLC, +1-707-226-3900, ext. 102
Web site: http://www.senetekplc.com/
